RARE vs SRTAW · rev $350.0M vs rev $248.7M
Ultragenyx (RARE) versus Strata Critical Medical, Inc. (SRTAW) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Strata Critical Medical, Inc. (SRTAW) common stock listed on NASDAQ.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported SRTAW revenue for 2024-12-31 was $248.7M. Net income was -$27.3M. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. SRTAW currently screens at market cap $0.
RARE currently screens at market cap $2.79B. SRTAW currently screens at market cap $0.
Not investment advice. Open the RARE and SRTAW stock pages for the full models.
Not investment advice.